DBV Technologies to Participate in Upcoming EAACI Congress 2025

Provided By GlobeNewswire

Last update: Jun 12, 2025

Châtillon, France, June 12, 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall.